BOSTON— A federal judge has blocked Massachusetts from banning the powerful new painkiller Zohydro. The judge issued a preliminary injunction Tuesday after pharmaceutical company, Zogenix, argued in a lawsuit that the ban issued by Gov.» Read More
Drug maker Eli Lilly reported first-quarter earnings and sales ahead of market expectations Monday and also boosted guidance for the year, thanks to strong sales of drugs for schizophrenia and depression.
Here's our look at contest stocks from Thursday's close to Friday's close. Old stand by Freemont General brought owners/sellers some new gains. The most active and widely held stocks remained pretty much the same as they have been. One of the best performers Cott, was up on consolidation news involving Cadbury. Here's the breakdown:
John Lechleiter President and Chief Operating Officer of Eli Lilly, told CNBC’s “Squawk Box” that sales of Zyprexa, a drug used to treat schizophrenia, are strong. “We continue to be very bullish about Zyprexa,” Lechleiter said Monday. “We saw 6% sales growth in the U.S. this quarter. We had 14% sales growth internationally.”
It’s Friday, and that means it’s time to huddle up for Cramer’s plays for next week. Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
Lucky Friday the 13th: As I’ve often detailed, there are many moving parts to getting breaking news on the air. "Friday the 13th" is the last day one might think the stars would decide to align to our benefit, but they did. Beverage maker Cott had been the subject of speculation all day, focusing on a possible merger with Cadbury Schweppes. It was halted before the New York Stock Exchange open for “news pending,” which, of course, only served to fuel that speculation. ...
Superstition be darned. Shares of Dow component Merck are trading above $50 intra-day. That's the first time they've crossed 50 since October 9, 2003--nearly one year before the company pulled Vioxx off the market. So, what's going on?
The maker of the FluMist vaccine said it was putting istself up for sale, causing its shares to surge more than 10%. MedImmune also said that certain major drugmakers had already indicated they might be interested in a takeover.
Merck shares rose sharply Friday after the drugmaker raised its outlook for first-quarter and full-year earnings, citing strong sales across its range of products, and said a federal court judge dismissed a class-action securities lawsuit against the company.
Inflation data could play a big role in setting the course for stocks, which so far are looking for direction ahead of the opening. Asia markets were mostly lower, while Europe's stock markets this morning are mostly higher.
Nobody stays best of breed forever. And no matter how you feel about a company's reputation, only the fundamentals matter at end of day. For that reason, you should never hesitate to clear a poor performer from your portfolio - no matter how much of a blue chip you think it is.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
Merck's new pain reliever drug Arcoxia, which was proposed as a successor to Vioxx, was rejected by a federal health advisory panel. A Food and Drug Administration drug safety expert earlier told the panel that the drug may increase substantially the risk of stroke and heart attack and is no more effective for pain relief than other medicines in the same class.
Hey everyone. Guest blogger Jeff Mishlove promised to give his contest stock picks for the whole week--and he's delivered. Here are his thoughts and his list of selections for Friday: The strategy of finding eligible stocks, below $8 billion in market cap, that have earning reports due out, has been relatively successful. On Thursday, two of the stocks on my recommended list for...
U.S. biotechnology company MedImmune has hired Goldman Sachs to explore a sale of the company, which has a market capitalization of $8.8 billion, people familiar with the situation said on Thursday.
The failure of rival heart drugs has put the spotlight on a novel GlaxoSmithKline compound that will reach a critical stage of testing this year, after languishing in development for years.
A trial of Celgene's cancer drug Revlimid was temporarily suspended as of April 4, according to the Southwest Oncology Group, or SWOG, which was running the late-stage trial.
Shares of U.K. supermarket group J. Sainsbury are up sharply over the last two years, as improving results helped the once-struggling retailer return to 10-year highs.
Good morning all. Parker Robinson and James Kraber remain in the top two positions, with James holding the 2nd and 4th positions, and remember Deborah Taft? She made a strong move back into third place. Parker's portfolio value stands at $2,796,103.27, up $3,000 from Monday on bonus bucks.
Amgen, theworld's largest biotechnology company, said after U.S. markets closed Tuesday that it appointed Robert Bradway as chief financial officer.
Since another pharmaceutical industry blog has already posted an item about this under the title, "Son of Vioxx...." and since I don't want to be accused of plagiarism or sexism I've opted for "Daughter of Vioxx".
ImClone Systems said that a late-stage trial of its cancer drug Erbitux failed to improve overall survival in patients with pancreatic cancer. Imclone shares fell as much as 11% to $37.58 following the announcment.